vs
Side-by-side financial comparison of EDGEWELL PERSONAL CARE Co (EPC) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
EDGEWELL PERSONAL CARE Co is the larger business by last-quarter revenue ($422.8M vs $281.3M, roughly 1.5× Guardant Health, Inc.). EDGEWELL PERSONAL CARE Co runs the higher net margin — -15.5% vs -45.7%, a 30.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -11.6%). Guardant Health, Inc. produced more free cash flow last quarter ($-54.2M vs $-137.5M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -16.0%).
The Edgewell Personal Care Company is an American multinational consumer products company headquartered in Shelton, Connecticut. It was formed in 2015 following the corporate spin-off from Energizer Holdings, Inc..
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
EPC vs GH — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $422.8M | $281.3M |
| Net Profit | $-65.7M | $-128.5M |
| Gross Margin | 38.1% | 64.6% |
| Operating Margin | -4.5% | -43.0% |
| Net Margin | -15.5% | -45.7% |
| Revenue YoY | -11.6% | 39.4% |
| Net Profit YoY | -3028.6% | -15.8% |
| EPS (diluted) | $-1.41 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $422.8M | $281.3M | ||
| Q3 25 | $600.5M | $265.2M | ||
| Q2 25 | $627.2M | $232.1M | ||
| Q1 25 | $580.7M | $203.5M | ||
| Q4 24 | $415.1M | $201.8M | ||
| Q3 24 | $517.6M | $191.5M | ||
| Q2 24 | $647.8M | $177.2M | ||
| Q1 24 | $599.4M | $168.5M |
| Q4 25 | $-65.7M | $-128.5M | ||
| Q3 25 | $-30.6M | $-92.7M | ||
| Q2 25 | $29.1M | $-99.9M | ||
| Q1 25 | $29.0M | $-95.2M | ||
| Q4 24 | $-2.1M | $-111.0M | ||
| Q3 24 | $8.8M | $-107.8M | ||
| Q2 24 | $49.0M | $-102.6M | ||
| Q1 24 | $36.0M | $-115.0M |
| Q4 25 | 38.1% | 64.6% | ||
| Q3 25 | 37.9% | 64.7% | ||
| Q2 25 | 42.8% | 65.0% | ||
| Q1 25 | 44.1% | 63.3% | ||
| Q4 24 | 41.6% | 61.6% | ||
| Q3 24 | 41.1% | 61.1% | ||
| Q2 24 | 44.3% | 59.1% | ||
| Q1 24 | 43.1% | 61.2% |
| Q4 25 | -4.5% | -43.0% | ||
| Q3 25 | -4.2% | -37.3% | ||
| Q2 25 | 8.6% | -45.9% | ||
| Q1 25 | 10.1% | -54.6% | ||
| Q4 24 | 2.2% | -62.4% | ||
| Q3 24 | 3.9% | -61.3% | ||
| Q2 24 | 12.8% | -56.8% | ||
| Q1 24 | 11.7% | -59.2% |
| Q4 25 | -15.5% | -45.7% | ||
| Q3 25 | -5.1% | -35.0% | ||
| Q2 25 | 4.6% | -43.0% | ||
| Q1 25 | 5.0% | -46.8% | ||
| Q4 24 | -0.5% | -55.0% | ||
| Q3 24 | 1.7% | -56.3% | ||
| Q2 24 | 7.6% | -57.9% | ||
| Q1 24 | 6.0% | -68.2% |
| Q4 25 | $-1.41 | $-1.01 | ||
| Q3 25 | $-0.65 | $-0.74 | ||
| Q2 25 | $0.62 | $-0.80 | ||
| Q1 25 | $0.60 | $-0.77 | ||
| Q4 24 | $-0.04 | $-0.90 | ||
| Q3 24 | $0.18 | $-0.88 | ||
| Q2 24 | $0.98 | $-0.84 | ||
| Q1 24 | $0.72 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $378.2M |
| Total DebtLower is stronger | $1.5B | $1.5B |
| Stockholders' EquityBook value | $1.5B | $-99.3M |
| Total Assets | $3.8B | $2.0B |
| Debt / EquityLower = less leverage | 1.03× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | — | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | $209.1M | $585.0M | ||
| Q2 24 | — | $933.7M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | $1.5B | $1.5B | ||
| Q3 25 | $1.4B | $1.1B | ||
| Q2 25 | $1.4B | $1.1B | ||
| Q1 25 | $1.4B | $1.1B | ||
| Q4 24 | $1.4B | $1.1B | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $1.5B | $-99.3M | ||
| Q3 25 | $1.6B | $-354.5M | ||
| Q2 25 | $1.6B | $-305.5M | ||
| Q1 25 | $1.5B | $-250.8M | ||
| Q4 24 | $1.5B | $-139.6M | ||
| Q3 24 | $1.6B | $-60.1M | ||
| Q2 24 | $1.6B | $-1.6M | ||
| Q1 24 | $1.6B | $68.3M |
| Q4 25 | $3.8B | $2.0B | ||
| Q3 25 | $3.8B | $1.3B | ||
| Q2 25 | $3.8B | $1.3B | ||
| Q1 25 | $3.8B | $1.3B | ||
| Q4 24 | $3.7B | $1.5B | ||
| Q3 24 | $3.7B | $1.5B | ||
| Q2 24 | $3.7B | $1.6B | ||
| Q1 24 | $3.8B | $1.7B |
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.89× | — | ||
| Q2 25 | 0.88× | — | ||
| Q1 25 | 0.95× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-125.9M | $-26.4M |
| Free Cash FlowOCF − Capex | $-137.5M | $-54.2M |
| FCF MarginFCF / Revenue | -32.5% | -19.3% |
| Capex IntensityCapex / Revenue | 2.7% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $36.3M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-125.9M | $-26.4M | ||
| Q3 25 | $74.1M | $-35.4M | ||
| Q2 25 | $114.8M | $-60.3M | ||
| Q1 25 | $45.1M | $-62.7M | ||
| Q4 24 | $-115.6M | $-64.5M | ||
| Q3 24 | $-388.3M | $-51.1M | ||
| Q2 24 | $101.2M | $-94.0M | ||
| Q1 24 | $129.0M | $-30.3M |
| Q4 25 | $-137.5M | $-54.2M | ||
| Q3 25 | $46.5M | $-45.8M | ||
| Q2 25 | $99.3M | $-65.9M | ||
| Q1 25 | $28.0M | $-67.1M | ||
| Q4 24 | $-132.4M | $-83.4M | ||
| Q3 24 | $-414.2M | $-55.3M | ||
| Q2 24 | $88.6M | $-99.1M | ||
| Q1 24 | $117.5M | $-37.2M |
| Q4 25 | -32.5% | -19.3% | ||
| Q3 25 | 7.7% | -17.3% | ||
| Q2 25 | 15.8% | -28.4% | ||
| Q1 25 | 4.8% | -33.0% | ||
| Q4 24 | -31.9% | -41.3% | ||
| Q3 24 | -80.0% | -28.9% | ||
| Q2 24 | 13.7% | -55.9% | ||
| Q1 24 | 19.6% | -22.1% |
| Q4 25 | 2.7% | 9.9% | ||
| Q3 25 | 4.6% | 3.9% | ||
| Q2 25 | 2.5% | 2.4% | ||
| Q1 25 | 2.9% | 2.2% | ||
| Q4 24 | 4.0% | 9.4% | ||
| Q3 24 | 5.0% | 2.2% | ||
| Q2 24 | 1.9% | 2.9% | ||
| Q1 24 | 1.9% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.95× | — | ||
| Q1 25 | 1.56× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -44.13× | — | ||
| Q2 24 | 2.07× | — | ||
| Q1 24 | 3.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
